ATE290880T1 - Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält - Google Patents
Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthältInfo
- Publication number
- ATE290880T1 ATE290880T1 AT01936440T AT01936440T ATE290880T1 AT E290880 T1 ATE290880 T1 AT E290880T1 AT 01936440 T AT01936440 T AT 01936440T AT 01936440 T AT01936440 T AT 01936440T AT E290880 T1 ATE290880 T1 AT E290880T1
- Authority
- AT
- Austria
- Prior art keywords
- inosine
- cytosine
- composition containing
- polycationic peptide
- antigen composition
- Prior art date
Links
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229930010555 Inosine Natural products 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 229940104302 cytosine Drugs 0.000 title 1
- 229960003786 inosine Drugs 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
| PCT/EP2001/006437 WO2001093903A1 (en) | 2000-06-08 | 2001-06-07 | Antigenic composition comprising a polycationic peptide and inosine and cytosine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE290880T1 true ATE290880T1 (de) | 2005-04-15 |
Family
ID=3683921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
| AT01936440T ATE290880T1 (de) | 2000-06-08 | 2001-06-07 | Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7148191B2 (de) |
| EP (1) | EP1286695B1 (de) |
| AT (2) | AT410173B (de) |
| AU (1) | AU2001262345A1 (de) |
| DE (1) | DE60109443T2 (de) |
| WO (1) | WO2001093903A1 (de) |
| ZA (1) | ZA200209479B (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046224A2 (en) * | 1999-12-22 | 2001-06-28 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| WO2001093905A1 (en) | 2000-06-08 | 2001-12-13 | Intercell Biomedizinische Forschungs- Und Entwicklungs Ag | Immunostimulatory oligodeoxynucleotides |
| AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| CA2433561C (en) * | 2001-01-03 | 2014-04-01 | Willmar Poultry Company, Inc. | Compositions including gram negative siderophore receptor proteins and methods of use |
| WO2002053185A2 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Anti-inflammatory use of polycationic compounds |
| EP1347775B1 (de) | 2001-01-05 | 2016-11-30 | Valneva Austria GmbH | Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe |
| CA2452909A1 (en) * | 2001-12-07 | 2003-06-13 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| CN1659436A (zh) * | 2002-02-28 | 2005-08-24 | 英特塞尔股份公司 | 分离配体的方法 |
| WO2003090685A2 (en) * | 2002-04-24 | 2003-11-06 | The Regents Of The University Of California | Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses |
| WO2005102278A1 (en) * | 2002-07-03 | 2005-11-03 | Oncovir, Inc. | Method for preparation of poly-iclc and uses thereof |
| CA2484941A1 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
| EP2314603A3 (de) | 2002-10-15 | 2011-05-18 | Intercell AG | Bindungdsfaktoren von Gruppe B-Streptococcus, dafür kodierende Nukleinsäuren und Verwendungen davon |
| AU2003297317A1 (en) * | 2002-12-13 | 2004-07-09 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
| EP1601770B1 (de) | 2003-03-04 | 2009-09-02 | Intercell AG | Streptococcus pyogenes antigene |
| CN100355453C (zh) * | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | 改进的疫苗 |
| ES2562456T3 (es) * | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
| EP1608756B1 (de) | 2003-03-31 | 2009-11-18 | Intercell AG | Staphylococcus epidermidis antigene |
| EP2333114A1 (de) | 2003-04-15 | 2011-06-15 | Intercell AG | S. pneumoniae Antigene |
| EP1620460A2 (de) | 2003-05-07 | 2006-02-01 | Intercell AG | Streptococcus agalactiae-antigene i + ii |
| CN102304527A (zh) | 2003-05-30 | 2012-01-04 | 英特塞尔股份公司 | 肠球菌抗原 |
| ES2395022T3 (es) * | 2003-09-19 | 2013-02-07 | Epitopix, Llc | Polipéptidos de Campylobacter y sus métodos de uso |
| CA2583026A1 (en) * | 2004-10-29 | 2006-05-04 | Intercell Ag | Hcv vaccines for chronic hcv patients |
| EP1853306B1 (de) | 2005-02-14 | 2016-06-15 | Epitopix, LLC | Polypeptide von staphylococcus aureus und methoden zu deren verwendung |
| EP2040745B1 (de) | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen |
| EP2319862A1 (de) | 2006-07-07 | 2011-05-11 | Intercell AG | Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür |
| WO2008031133A2 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| EP1923069A1 (de) | 2006-11-20 | 2008-05-21 | Intercell AG | Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen |
| US8343510B2 (en) | 2007-01-12 | 2013-01-01 | Intercell Ag | Protective proteins of S. agalactiae, combinations thereof and methods of using the same |
| US20090041809A1 (en) * | 2007-03-07 | 2009-02-12 | Nventa Biopharmaceuticals Corporation | Double-stranded locked nucleic acid compositions |
| EP2152731A2 (de) | 2007-05-02 | 2010-02-17 | Intercell AG | Klebsiella-antigene |
| EP2012122A1 (de) | 2007-07-06 | 2009-01-07 | Medigene AG | Strukturproteine von mutierten Parvoviren als Impfstoffe |
| WO2008145400A2 (en) | 2007-05-31 | 2008-12-04 | Medigene Ag | Mutated structural protein of a parvovirus |
| AU2008265218A1 (en) | 2007-06-18 | 2008-12-24 | Intercell Ag | Chlamydia antigens |
| JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
| EP2247308A4 (de) * | 2008-01-10 | 2012-04-18 | Nventa Biopharmaceuticals Corp | Hilfsstoffzusammensetzungen mit poly-ic und einem kationischen polymer |
| CN101977927A (zh) | 2008-03-17 | 2011-02-16 | 英特塞尔股份公司 | 针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途 |
| CN102056622B (zh) | 2008-06-05 | 2016-04-06 | 免疫疫苗技术有限公司 | 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物 |
| WO2009156960A2 (en) | 2008-06-27 | 2009-12-30 | Pfizer Inc. | Novel adjuvant compositions |
| US20130243779A1 (en) | 2009-02-05 | 2013-09-19 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
| EP2405938A2 (de) | 2009-02-13 | 2012-01-18 | Intercell AG | Nicht typisierbare haemophilus influenza-antigene |
| EP2411046B1 (de) | 2009-03-23 | 2017-12-06 | Epitopix, LLC | Polypeptide und immunisierungszusammensetzungen mit gram-prositiven polypeptiden und anwendungsverfahren |
| EP2308896A1 (de) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
| WO2011042548A1 (en) | 2009-10-09 | 2011-04-14 | Sanofi-Aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| EP2319871A1 (de) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
| SMT201700124T1 (it) | 2010-09-03 | 2017-05-08 | Valneva Austria Gmbh | Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi |
| AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| WO2012139094A2 (en) | 2011-04-08 | 2012-10-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of developing a vaccine using peptide-poly ic complexes |
| UA121200C2 (uk) | 2013-09-19 | 2020-04-27 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| EP4248992A3 (de) | 2015-01-16 | 2023-12-27 | Zoetis Services LLC | Impfstoffs gegen maul- und klauenseuche |
| US10166280B2 (en) | 2016-06-08 | 2019-01-01 | Epitopix, Llc | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use |
| JP2021513840A (ja) | 2018-02-16 | 2021-06-03 | ２エー ファーマ アーベー | 自己免疫疾患の処置のためのパルボウイルス構造タンパク質 |
| EP3527223A1 (de) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutiertes parvovirus-strukturprotein |
| PH12021552736A1 (en) | 2019-05-20 | 2022-07-11 | Valneva Se | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| WO2020240268A1 (en) | 2019-05-31 | 2020-12-03 | Universidad De Chile | An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec) |
| US20230372464A1 (en) | 2020-10-07 | 2023-11-23 | Valneva Sweden Ab | Cholera vaccine formulation |
| US20240358812A1 (en) | 2021-04-09 | 2024-10-31 | Valneva Se | Human metapneumovirus combination vaccine |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR6801650D0 (pt) | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
| US3725545A (en) * | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
| CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
| EP0934330A1 (de) | 1996-07-24 | 1999-08-11 | Michelle M. Hanna | Basengeschuetzte nukleotid-analoge mit geschuetzten thiolgruppen |
| ATE375169T1 (de) * | 2000-04-14 | 2007-10-15 | Intercell Ag | Modifizierte peptide enthaltende pharmazeutische präparationen |
| AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
-
2000
- 2000-06-08 AT AT0100000A patent/AT410173B/de not_active IP Right Cessation
-
2001
- 2001-06-07 AU AU2001262345A patent/AU2001262345A1/en not_active Abandoned
- 2001-06-07 DE DE60109443T patent/DE60109443T2/de not_active Expired - Lifetime
- 2001-06-07 EP EP01936440A patent/EP1286695B1/de not_active Expired - Lifetime
- 2001-06-07 AT AT01936440T patent/ATE290880T1/de active
- 2001-06-07 WO PCT/EP2001/006437 patent/WO2001093903A1/en not_active Ceased
- 2001-06-07 US US10/297,497 patent/US7148191B2/en not_active Expired - Lifetime
-
2002
- 2002-11-21 ZA ZA200209479A patent/ZA200209479B/en unknown
-
2006
- 2006-12-12 US US11/609,777 patent/US20070218073A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001093903A1 (en) | 2001-12-13 |
| ZA200209479B (en) | 2003-11-21 |
| DE60109443D1 (de) | 2005-04-21 |
| AT410173B (de) | 2003-02-25 |
| DE60109443T2 (de) | 2006-04-13 |
| US7148191B2 (en) | 2006-12-12 |
| EP1286695B1 (de) | 2005-03-16 |
| ATA10002000A (de) | 2002-07-15 |
| EP1286695A1 (de) | 2003-03-05 |
| US20030162738A1 (en) | 2003-08-28 |
| US20070218073A1 (en) | 2007-09-20 |
| AU2001262345A1 (en) | 2001-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60109443D1 (de) | Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| ATE500323T1 (de) | Subtilisin-variante | |
| NZ503763A (en) | Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use | |
| ATE404583T1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
| TR200003513T2 (tr) | Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları | |
| AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
| DE60037450D1 (de) | Funf-helix protein | |
| SE0002102D0 (sv) | Chemical compound | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| CL2009000575A1 (es) | Anticuerpos aislados anti-interleuquina 12 (anti il-12) de mamiferos, secuencia de nucleotidos, vector, celula y metodo de produccion, composicion y dispositivo medico que contienen, util en el diagnostico y tratamiento de condicones relacionadas con il-12. | |
| YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
| CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
| ATE247484T1 (de) | Von der telomerase abgeleitete antigene peptide | |
| BR9710968A (pt) | Antìgenos de célula b humana; reagentes correlatos | |
| BR0114646A (pt) | anticorpos anti-lt-beta-r humanizados | |
| NI200800193A (es) | Anticuerpos humanos anti-il-23, composiciones, métodos y usos. | |
| ATE267211T1 (de) | Impfstoff gegen hpv | |
| TR199900267T2 (xx) | GnRH-L�kotoksin kimeralar�. | |
| DE69111440D1 (de) | Methoden und zusammensetzungen zur impfung gegen hiv. | |
| ATE384119T1 (de) | Isoprenoidproduktion | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| DE60129572D1 (de) | Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1286695 Country of ref document: EP |